COMMUNIQUÉS West-GlobeNewswire

Lexicon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update

02/05/2024 - 22:05

Commercial launch of INPEFA ® (sotagliflozin) for Heart Failure continues to progress Resubmission of NDA for ZYNQUISTA ™ (sotagliflozin) in Type 1 Diabetes expected mid-year 2024 Start-up ongoing for Phase 3 study of [...]

The Joint Corp. Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

- Grew Q1 2024 Revenue 5%, System-wide Sales 9%, and System-wide Comp Sales 3% vs. Q1 2023 - - Opened 23 Franchised Clinics, Increasing Clinic Count to 954 at March 31, 2024 - - Sold 15 Franchise Licenses, Tripling [...]

NextCure Provides Business Update and Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

Phase 1b data for NC410 combo with pembro to be presented at ASCO annual meeting on June 1 Presented preclinical data from LNCB74 (B7-H4 ADC) at recent AACR annual meeting Cash of approximately $96.0 million expected to [...]

OrthoPediatrics Corp. Receives “Breakthrough Device” Designation from FDA for eLLi™ Growing Rod System for Pediatric Patients with Scoliosis

02/05/2024 - 22:05

WARSAW, Ind., May 02, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced it has received the [...]

Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

02/05/2024 - 22:05

MENLO PARK, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]

Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

02/05/2024 - 22:05

SILVER SPRING, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a company pioneering drug-eluting biomatrix products, today announced that it will release its first quarter 2024 financial [...]

ClearPoint Neuro to Present Novel Research and Exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting in Baltimore

02/05/2024 - 22:05

SOLANA BEACH, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, [...]

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

02/05/2024 - 22:05

Reported positive data from the escalation portion of Phase 1/2 study (COVALENT-111) in type 2 diabetes patients, displaying durable improved glycemic control while off therapy for 22 weeks, supporting the disease- [...]

Codexis Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

Q1 Total Revenue Up 32% Year-over-year, Including Product Revenue Up 14%; Company Reiterates 2024 Financial Guidance First Substantial Order for dsRNA Ligase Received from Large Pharma Customer Company is in Final [...]

Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results

02/05/2024 - 22:05

Reported $420.5 million in cash resources as of March 31, 2024, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027 Completion of rolling biologics [...]

Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update

02/05/2024 - 22:02

Company reports $45.6 million in Q1 product-related revenue, including $28.4 million in net product sales revenue for IBSRELA and $15.2 million in net product sales revenue for XPHOZAH Company ends Q1 with approximately [...]

Corvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024

02/05/2024 - 22:02

Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT BURLINGAME, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today [...]

Soleno Therapeutics Announces Proposed Public Offering of Common Stock

02/05/2024 - 22:01

REDWOOD CITY, Calif., May 02, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of [...]

Mustang Bio Announces Closing of $4 Million Public Offering

02/05/2024 - 22:01

Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 Million WORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage [...]

WW International, Inc. Announces First Quarter 2024 Results

02/05/2024 - 22:01

End of Period Subscribers of 4.0 million, including 91 thousand End of Period Clinical Subscribers Revenues of $206.5 million Gross margin of 66.7%; excluding the net impact of restructuring charges related to prior [...]

Vor Bio Appoints Accomplished Oncology and Cancer Immunotherapy R&D Executive, Fouad Namouni, M.D., to its Board of Directors

02/05/2024 - 22:01

CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. [...]

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

02/05/2024 - 22:01

Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Monte Rosa [...]

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update

02/05/2024 - 22:01

VANCOUVER, British Columbia, May 02, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced it will report its first quarter 2024 financial [...]

Alignment Healthcare Reports First Quarter 2024 Results

02/05/2024 - 22:01

Reports $628.6 million in total revenue and $627.6 million in revenue excluding ACO REACH, up 43.1% and 54.2% y ear-over-year respectively Medicare Advantage membership grows 50.5% year-over-year to approximately 165, [...]